IL33 and Alzheimer disease: In the APPswe, PSEN1dE9 (APP/PS1) double transgenic mouse, an AD mouse model, IL-33 administration reduces soluble Aβ levels and amyloid plaque deposition by enhancing microglial recruitment, Aβ phagocytic activity and anti-inflammatory responses via ST2/MAPK signaling, ultimately contributing to the amelioration of AD development (92).